Compare PCRX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | MAX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 516.4M |
| IPO Year | 2010 | 2020 |
| Metric | PCRX | MAX |
|---|---|---|
| Price | $23.19 | $9.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $37.20 | $12.70 |
| AVG Volume (30 Days) | ★ 573.7K | 521.8K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | 25.81 |
| EPS | 0.16 | ★ 0.39 |
| Revenue | $541,533,000.00 | ★ $1,113,600,000.00 |
| Revenue This Year | $6.78 | $13.42 |
| Revenue Next Year | $8.54 | $8.16 |
| P/E Ratio | $140.69 | ★ $24.49 |
| Revenue Growth | 26.04 | ★ 28.78 |
| 52 Week Low | $18.80 | $7.09 |
| 52 Week High | $27.99 | $13.92 |
| Indicator | PCRX | MAX |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 54.12 |
| Support Level | $22.57 | $9.31 |
| Resistance Level | $23.94 | $11.10 |
| Average True Range (ATR) | 0.77 | 0.39 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 61.42 | 84.98 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.